迈克生物：接受创金合信基金管理有限公司等投资者调研

Group 1 - The core point of the article is that Maike Bio (SZ 300463) announced an investor meeting scheduled for October 27, 2025, where the company's CFO, Yin Shan, will participate and address investor inquiries [1] - For the first half of 2025, Maike Bio's revenue composition is entirely from in vitro diagnostics, accounting for 100.0% of its revenue [1] - As of the report date, Maike Bio has a market capitalization of 7 billion yuan [1]